USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
26 Apr 2022 | 07:00 AM GMT

Do’s & Don’ts when building the Evidence Generation Strategy for DTx

Anchored by:

Matt Norton
VP of Marketing & Commercial Development
S3 CONNECTED HEALTH

Participants:

Matt Norton VP of Marketing & Commercial DevelopmentS3 Connected Health
Matt Norton
VP of Marketing & Commercial DevelopmentS3 Connected Health
Chandana Fitzgerald President, CommunityHLTH
Chandana Fitzgerald
President, CommunityHLTH
Lahiru Russell Strategic Fellow (Evaluation)Deakin University, Faculty of Health
Lahiru Russell
Strategic Fellow (Evaluation)Deakin University, Faculty of Health
Mansa Shroff Director of Business Dev & Chief of StaffWKD.SMRT
Mansa Shroff
Director of Business Dev & Chief of StaffWKD.SMRT
Tim Ruckh Digital Health Clinical Data Collection LeadAstraZeneca
Tim Ruckh
Digital Health Clinical Data Collection LeadAstraZeneca

About this Meeting

Are you struggling with building the right evidence generation strategy for your DTx? Finding the right evidence generation strategy for a DTx product can be an arduous task to do, this is why we are organizing this peer-to-peer session where all participants can learn from each other’s knowledge and experiences. Join this session to discuss the following with the HealthXL DTx community: 

  • What are the evidence requirements from the different stakeholders and how to address all of them as efficiently as possible? How does this depend on the type of product (PDT vs. nPDT, standalone vs. drug-DTx combo)?  
  • The evidence required will change depending on the routes to market you want to take and the claims you need. How to successfully build your evidence generation strategy hand in hand with your commercialization strategy? 
  • Challenges & Best practices in clinical study design: comparators, endpoint selection, participants diversity, etc. 
  • Health economic studies: when are these necessary? What are the best practices to get meaningful economic data?